Nilotinib (Nilotinib)
Overview of Nilotinib
Nilotinib is an antineoplastic agent and shows its activity through tyrosine kinase inhibitor that is used for the treatment of chronic myeloid leukaemia.chemically it is Nilotinibum. 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]- amino}benzamide
Indication of Nilotinib
Nilotinib is primarily indicated in conditions like Myeloid leukaemia.
Contraindication of Nilotinib
No data regarding the contra indications of Nilotinib is available.
Side Effects of Nilotinib
The severe or irreversible adverse effects of Nilotinib, which give rise to further complications include Thrombocytopenia, Neutropenia, Pneumonia, Leukopenia, febrile neutropenia, intracranial hemorrhage, pyrexia, febrile neutropenia, intracranial hemorrhage, eleated lipase.,The symptomatic adverse reactions produced by Nilotinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Nausea, Vomiting, Diarrhea, Pruritis, Rash.
Precautions of Nilotinib
Myelosuppression: Associated with neutropenia, thrombocytopenia and anemia. CBC should be done every 2 weeks for the first 2 months, then monthly. Reversible by withholding dose. Dose reduction may be required. nilotinib prolongs the QT interval. Correct hypokalemia or hypomagnesemia prior to administration and monitor periodically.Caution is recommended in patients with history of pancreatitis. Check serum lipase periodically. nilotinib may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase. Check hepatic function tests periodically. nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Tasigna and monitor periodically during therapy. Food increases blood levels of nilotinib . Avoid food 2 hours before and 1 hour after a dose.Fetal harm can occur when administered to a pregnant woman.